Post by Kymera Therapeutics

At the Japanese Dermatological Association Annual Meeting, we presented Phase 1 data in healthy Japanese adults for KT-621, our investigational, first-in-class, oral STAT6 degrader. The presentation highlights KT-621’s compelling profile and its potential to transform treatment paradigms for patients living with chronic Type 2 inflammatory conditions. Learn more in our latest press release: https://bit.ly/443iypp #RevolutionizingImmunology